Vascular Disrupting Agents Market Size, Share & Trends Analysis Report By Indication, By Therapeutic Area (Hematological Malignancies, Solid Tumors), By Product, By Molecule, By Therapy, By Route of Administration, By Region, And By Segment Forecasts, 2029-2034.

Report Id: 1299 Pages: 180 Last Updated: 26 May 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Vascular Disrupting Agents Market

Global Vascular Disrupting Agents Market, by Indications, 2020-2030 (Valu US$ Mn)

  • Chemotherapy-Induced Neutropenia
  • Glioblastoma
  • Liver Cancer
  • Mesothelioma
  • Non-Small Cell Lung Cancer
  • Prostate Cancer
  • Ovarian Cancer
  • Renal Pelvis
  • Ureter Cancer

Vascular Disrupting Agents Market

Global Vascular Disrupting Agents Market, by Therapeutic Area, 2020-2030 (Valu US$ Mn)

  • Hematological Malignancies
  • Solid Tumors

Global Vascular Disrupting Agents Market, by Molecules, 2020-2030 (Value US$ Mn)

  • Tubulin Binding Agents
  • Flavonoids
  • Ligand-Directed Agents

Global Vascular Disrupting Agents Market, by Therapy, 2020-2030 (Valu US$ Mn)

  • Mono
  • Combination

Global Vascular Disrupting Agents Market, by Route of Administration, 2020-2030 (Value US$ Mn)

  • Oral
  • Intravenous

Global Vascular Disrupting Agents Market, by Product, 2020-2030 (Valu US$ Mn)

  • Bavituximab
  • Icaritin
  • NGR-TNF
  • Padeliporfin
  • Plinabulin
  • VB-111
  • Others

Global Vascular Disrupting Agents Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Vascular Disrupting Agents Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Landscape

  • Company Overview
  • Financial Performance
  • Key Development
  • Latest Strategic Developments

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Vascular Disrupting Agents Market Snapshot

Chapter 4. Global Vascular Disrupting Agents Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Indication, Estimates & Trend Analysis

5.1. By Indications, & Market Share, 2029 & 2034

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Indications:

5.2.1. Chemotherapy-Induced Neutropenia

5.2.2. Glioblastoma

5.2.3. Liver Cancer

5.2.4. Mesothelioma

5.2.5. Non-Small Cell Lung Cancer

5.2.6. Prostate Cancer

5.2.7. Ovarian Cancer

5.2.8. Renal Pelvis

5.2.9. Ureter Cancer

Chapter 6. Market Segmentation 2: By Therapeutic Area Estimates & Trend Analysis

6.1. By Therapeutic Area & Market Share, 2029 & 2034

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapeutic Area:

6.2.1. Hematological Malignancies

6.2.2. Solid Tumors

Chapter 7. Market Segmentation 3: By Molecule Estimates & Trend Analysis

7.1. By Molecule & Market Share, 2029 & 2034

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Molecule:

7.2.1. Tubulin Binding Agents

7.2.2. Flavonoids

7.2.3. Ligand-Directed Agents

Chapter 8. Market Segmentation 4: By Therapy Estimates & Trend Analysis

8.1. By Therapy & Market Share, 2029 & 2034

8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Therapy

8.2.1. Mono

8.2.2. Combination

Chapter 9. Market Segmentation 5: By Route of Administrations Estimates & Trend Analysis

9.1. By Route of Administrations & Market Share, 2029 & 2034

9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Route of Administrations:

9.2.1. Oral

9.2.2. Intravenous

Chapter 10. Market Segmentation 6: By Products Estimates & Trend Analysis

10.1. By Products & Market Share, 2029 & 2034

10.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Products:

10.2.1. Bavituximab

10.2.2. Icaritin

10.2.3. NGR-TNF

10.2.4. Padeliporfin

10.2.5. Plinabulin

10.2.6. VB-111

10.2.7. Other Products

Chapter 11. Vascular Disrupting Agents Market Segmentation 7: Regional Estimates & Trend Analysis

11.1. North America

11.1.1. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Indications, 2021-2034

11.1.2. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Therapeutic Area, 2021-2034

11.1.3. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts By Molecule, 2021-2034

11.1.4. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034

11.1.5. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034

11.1.6. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034

11.1.7. North America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by country, 2021-2034

11.2. Europe

11.2.1. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2021-2034

11.2.2. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2021-2034

11.2.3. Europe Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2021-2034

11.2.4. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034

11.2.5. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034

11.2.6. Europe Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034

11.2.7. Europe Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034

11.3. Asia Pacific

11.3.1. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Indications, 2021-2034

11.3.2. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, 2021-2034

11.3.3. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, 2021-2034

11.3.4. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034

11.3.5. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034

11.3.6. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034

11.3.7. Asia Pacific Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034

11.4. Latin America

11.4.1. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034

11.4.2. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034

11.4.3. Latin America Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034

11.4.4. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034

11.4.5. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034

11.4.6. Latin America Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034

11.4.7. Latin America Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034

11.5. Middle East & Africa

11.5.1. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Indications, (US$ Million) 2021-2034

11.5.2. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Therapeutic Area, (US$ Million) 2021-2034

11.5.3. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) By Molecule, (US$ Million) 2021-2034

11.5.4. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Therapy, 2021-2034

11.5.5. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Route of Administration, 2021-2034

11.5.6. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) estimates and forecasts by Products, 2021-2034

11.5.7. Middle East & Africa Vascular Disrupting Agents Market revenue (US$ Million) by country, 2021-2034

Chapter 12. Competitive Landscape

12.1. Major Mergers and Acquisitions/Strategic Alliances

12.2. Company Profiles 

12.2.1. AGC Biologics

12.2.2. Avid Bioservices

12.2.3. Bionomics

12.2.4. Beijing Shenogen Biomedical

12.2.5. Mateon Therapeutics

12.2.6. Myrexis

12.2.7. VBL Therapeutics

12.2.8. Steba biotech

12.2.9. BeyondSpring Pharmaceuticals

12.2.10. Immune Pharmaceuticals

12.2.11. Nereus Pharmaceuticals

12.2.12. Madrigal Pharmaceuticals, Inc.

12.2.13. Celgene Corporation

12.2.14. Bionomics Ltd.

12.2.15. Lees Pharmaceutical Holdings.

12.2.16. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
4961
Security Code field cannot be blank!

Frequently Asked Questions

AGC Biologics (Denmark), Avid Bioservices (US), Bionomics (Australia), Beijing Shenogen Biomedical (China), Mateon Therapeutics (US), Myrexis (US), VB

The Vascular Disrupting Agents Market is expected to grow at a 10% CAGR during the forecast period for 2029-2034.

Indications, therapeutic area, molecules, therapy, route of administration, and product are the key segments of the Vascular Disrupting Agents Market

North American region is leading the Vascular Disrupting Agents Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying